New Brunswick, NJ, United States of America

Ravindra W Tejwani



 

Average Co-Inventor Count = 6.1

ph-index = 5

Forward Citations = 80(Granted Patents)


Location History:

  • Somerset, NJ (US) (2003 - 2010)
  • New Brunswick, NJ (US) (2010 - 2014)
  • Monmouth Junction, NJ (US) (2015 - 2022)

Company Filing History:


Years Active: 2003-2022

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Ravindra W Tejwani: Innovator in Pharmaceutical Formulations

Introduction

Ravindra W Tejwani is a notable inventor based in New Brunswick, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work primarily focuses on innovative formulations that enhance the efficacy of various medications.

Latest Patents

Among his latest patents, Ravindra has developed formulations of pimavanserin. These patents include capsules containing pimavanserin, processes for manufacturing said capsules, and pharmaceutical compositions that incorporate this compound. Additionally, he has created pharmaceutical formulations containing an SGLT2 inhibitor. These formulations are designed for oral use and include the medicament dapagliflozin or its propylene glycol hydrate, along with a pharmaceutical acceptable carrier, aimed at immediate release.

Career Highlights

Ravindra has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Bristol-Myers Squibb Company and AstraZeneca AB, where he contributed to the development of innovative drug formulations.

Collaborations

Throughout his career, Ravindra has collaborated with several talented individuals, including Mandar V Dali and Dilbir S Bindra. These collaborations have further enriched his work and contributed to the advancement of pharmaceutical sciences.

Conclusion

Ravindra W Tejwani's contributions to pharmaceutical formulations demonstrate his commitment to innovation in the field. His patents reflect a deep understanding of drug development and a dedication to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…